Lutetium-177 Rosopatamab Tetraxetan for Metastatic Prostate Cancer

Lutetium-177 Rosopatamab Tetraxetan for Metastatic Prostate Cancer
49%35%20%May 18May 19May 20May 21May 22May 23May 24May 25May 26May 27May 28May 21 • YES 24.8%May 22 • YES 44.5%May 24 • YES 40.7%May 26 • YES 36.7%May 27 • YES 33.3%May 28 • YES 37.2%
Telix Pharmaceuticals (Innovations) Pty Limited ($TLX)
No stock close$10.41$9.88$9.34May 18May 19May 20May 21May 22May 23May 24May 25May 26May 27May 28May 18 • TLX $10.28May 19 • TLX $10.17May 20 • TLX $10.28May 21 • TLX $10.27May 22 • TLX $9.47May 26 • TLX $9.57May 27 • TLX $9.74

Will this trial show a positive result on overall Survival?

Paper Trading
Create account to trade
ClinicalNewsTrialPositionsReasoningOracle
Primary Completion
12/1/27
Study Completion
12/1/30
Sponsor
Telix Pharmaceuticals (Innovations) Pty Limited
Ticker
$TLX
Type
Phase 3
Trial Status
Recruiting
Trial Size
520
NCT
NCT06520345
Trial Description
This Phase 3 trial tests lutetium-177 rosopatamab tetraxetan in men with PSMA-positive metastatic castration-resistant prostate cancer, measuring time without imaging-confirmed progression.